survey
Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology
Precision Oncology News' 2022 survey showed doctors are increasingly offering molecular testing to earlier-stage patients, but institutions still need to do better to ensure patients have equitable access.
The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.
The findings underscore the importance of ongoing research that will provide critical evidence supporting when MRD status can be used to intensify or de-escalate treatment.
Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology
An AstraZeneca-funded survey suggests that efforts to improve precision oncology access must focus on bridging stakeholders' disagreements about the barriers limiting adoption.
Survey of Precision Oncology Programs Shows Rapid Pace of Advances a Major Challenge for Oncologists
Results from Precision Oncology News' survey indicate that keeping up with the fast-changing treatment landscape has overtaken reimbursement as the top challenge for doctors.